Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days

  1. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

    Conditions:   Advanced Extrapulmonary Neuroendocrine Carcinoma;   Metastatic Extrapulmonary Neuroendocrine Carcinoma;   Recurrent Extrapulmonary Neuroendocrine Carcinoma;   Unresectable Extrapulmonary Neuroendocrine Carcinoma
    Interventions:   Biological: Atezolizumab;   Procedure: Biospecimen Collection;   Drug: Carboplatin;   Drug: Cisplatin;   Procedure: Computed Tomography;   Drug: Etoposide;   Procedure: Magnetic Resonance Imaging;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  2. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

    Condition:   Neuroendocrine Tumors
    Interventions:   Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT;   Drug: CAPTEM (Capecitabine and Temozolomide);   Other: Amino-Acid Solution;   Drug: Everolimus;   Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
    Sponsor:   ITM Solucin GmbH
    Recruiting

  3. Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

    Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:   Drug: 68-Gallium DOTATATE
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  4. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

    Condition:   Metastatic Neuroendocrine Tumor
    Interventions:   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Drug: Lutetium Lu 177 Dotatate;   Procedure: Magnetic Resonance Imaging;   Drug: Triapine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  5. A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

    Condition:   Advanced Neuroendocrine Carcinoma
    Interventions:   Drug: Surufatinib plus Toripalimab;   Drug: 5-fluorouracil, Calcium folinate and Irinotecan
    Sponsor:   Hutchison Medipharma Limited
    Recruiting

  6. Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

    Conditions:   Neuroendocrine Carcinoma;   Digestive Cancer
    Interventions:   Drug: Neoadjuvant treatment;   Drug: Adjuvant treatment
    Sponsors:   GERCOR - Multidisciplinary Oncology Cooperative Group;   Fondation ARCAD
    Recruiting

  7. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    Conditions:   Advanced Lung Carcinoid Tumor;   Functioning Lung Carcinoid Tumor;   Locally Advanced Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Neuroendocrine Neoplasm;   Lung Typical Carcinoid Tumor;   Metastatic Lung Carcinoid Tumor;   Metastatic Lung Neuroendocrine Neoplasm;   Non-Functioning Lung Carcinoid Tumor;   Recurrent Lung Neuroendocrine Neoplasm;   Unresectable Lung Carcinoid Tumor;   Unresectable Lung Neuroendocrine Neoplasm
    Interventions:   Drug: Everolimus;   Drug: Lutetium Lu 177 Dotatate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  8. Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

    Conditions:   EGFR-Mutated Non-Small-Cell Lung Carcinoma;   Small Cell/Neuroendocrine
    Interventions:   Drug: Olaparib;   Drug: Durvalumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  9. Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

    Conditions:   Small Cell Neuroendocrine Carcinoma;   Prostate Cancer;   Small Cell Carcinoma
    Interventions:   Drug: Apalutamide;   Biological: Cetrelimab
    Sponsors:   Rahul Aggarwal;   Janssen Scientific Affairs, LLC
    Recruiting

  10. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Digestive System Neuroendocrine Neoplasm;   Locally Advanced Digestive System Neuroendocrine Tumor G1;   Locally Advanced Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Lung Carcinoid Tumor;   Metastatic Lung Neuroendocrine Neoplasm;   Metastatic Pancreatic Neuroendocrine Neoplasm;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Thymic Carcinoid Tumor;   Unresectable Digestive System Neuroendocrine Neoplasm;   Unresectable Digestive System Neuroendocrine Tumor G1;   Unresectable Lung Neuroendocrine Neoplasm;   Unresectable Pancreatic Neuroendocrine Neoplasm;   Unresectable Thymic Neuroendocrine Neoplasm
    Interventions:   Drug: Cabozantinib S-malate;   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Procedure: X-Ray Imaging
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  11. Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

    Conditions:   Metastatic Midgut Neuroendocrine Tumor;   Unresectable Midgut Neuroendocrine Tumor
    Interventions:   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Drug: Everolimus;   Drug: Lutetium Lu 177 Dotatate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  12. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor;   Von Hippel-Lindau Disease;   Advanced Gastrointestinal Stromal Tumor;   HIF-2α Mutated Cancers
    Intervention:   Drug: Belzutifan
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  13. A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

    Condition:   Neuroendocrine Carcinoma
    Intervention:   Drug: Surufatinib and Serplulimab
    Sponsor:   Wuhan Union Hospital, China
    Not yet recruiting

  14. Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning;   Drug: Amino Acid infusion
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  15. A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

    Conditions:   Prostate Cancer;   Neuroendocrine Tumors;   Small Cell Carcinoma
    Interventions:   Drug: BXCL701 plus Pembrolizumab;   Drug: BXCL701 monotherapy
    Sponsor:   BioXcel Therapeutics Inc
    Recruiting

  16. Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

    Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  17. A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

    Conditions:   HRD Cancer;   SCLC;   Advanced Solid Tumors
    Interventions:   Drug: Berzosertib;   Drug: Sacituzumab Govitecan
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  18. A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

    Conditions:   Lung Neuroendocrine Neoplasm;   GEP Neuroendocrine Tumor
    Intervention:   Drug: Cabozantinib and Temozolomide
    Sponsor:   National Cancer Institute, Naples
    Recruiting

  19. Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

    Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Urothelial Cancer;   Poorly Differentiated Neuroendocrine Carcinomas;   Homologous Recombination Deficient-Positive Malignancies Agnostic
    Intervention:   Drug: Lurbinectedin
    Sponsor:   Jazz Pharmaceuticals
    Recruiting

  20. Study of Oral MRT-2359 in Selected Cancer Patients

    Conditions:   NSCLC;   SCLC;   High Grade Neuroendocrine Cancer;   DLBCL;   L-MYC and N-MYC Amplified Solid Tumors;   NSCLC With High or Low L-MYC or N-MYC Expression;   SCLC With High or Low L-MYC or N-MYC Expression
    Intervention:   Drug: Oral MRT-2359
    Sponsor:   Monte Rosa Therapeutics, Inc
    Recruiting

  21. Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

    Conditions:   Solid Tumor;   Non Small Cell Lung Cancer;   Neuroendocrine Carcinoma
    Interventions:   Biological: VSV-IFNβ-NIS;   Biological: Pembrolizumab
    Sponsors:   Vyriad, Inc.;   Mayo Clinic
    Recruiting

  22. Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

    Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  23. Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) - Pilot Study

    Condition:   Traumatic Injury of the Spinal Cord
    Intervention:   Drug: HBO
    Sponsor:   Medical University of Graz
    Recruiting

  24. A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder

    Condition:   Binge-eating Disorder
    Interventions:   Drug: TNX-1900 (Tonix Pharmaceuticals);   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Recruiting

  25. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Invasive Bladder Giant Cell Urothelial Carcinoma;   Invasive Bladder Lymphoepithelioma-Like Carcinoma;   Invasive Bladder Nested Urothelial Carcinoma;   Invasive Bladder Plasmacytoid Urothelial Carcinoma;   Invasive Bladder Sarcomatoid Urothelial Carcinoma;   Invasive Bladder Urothelial Carcinoma;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Malignant Testicular Leydig Cell Tumor;   Malignant Testicular Sertoli Cell Tumor;   Metastatic Bladder Carcinoma;   Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma;   Metastatic Bladder Giant Cell Urothelial Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Lipid-Rich Urothelial Carcinoma;   Metastatic Bladder Micropapillary Urothelial Carcinoma;   Metastatic Bladder Plasmacytoid Urothelial Carcinoma;   Metastatic Bladder Sarcomatoid Urothelial Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Chromophobe Renal Cell Carcinoma;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Papillary Renal Cell Carcinoma;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Urachal Adenocarcinoma;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Procedure: Bone Scan;   Drug: Cabozantinib S-malate;   Procedure: Computed Tomography;   Biological: Ipilimumab;   Procedure: Magnetic Resonance Imaging;   Biological: Nivolumab;   Procedure: Positron Emission Tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  26. Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

    Conditions:   Aggressive Variant Prostate Carcinoma;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Prostate Neuroendocrine Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Stage IV Prostate Cancer AJCC v8
    Interventions:   Drug: Cabazitaxel;   Drug: Carboplatin;   Biological: Cetrelimab;   Drug: Niraparib
    Sponsors:   M.D. Anderson Cancer Center;   Janssen Pharmaceutica
    Recruiting

  27. Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

    Conditions:   Appendix Carcinoma;   Colon Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Malignant Digestive System Neoplasm;   Pancreatic Carcinoma;   Rectal Carcinoma;   Small Intestinal Carcinoma;   Anal Carcinoma;   Digestive System Carcinoma;   Digestive System Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor
    Interventions:   Procedure: Acupuncture Therapy;   Procedure: Acupressure Therapy;   Procedure: Oral Cryotherapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   The Safeway Foundation
    Recruiting

  28. Non-Viral TCR Gene Therapy

    Conditions:   Endocrine/Neuroendocrine;   Non-Small Cell Lung Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Ovarian Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Biological: Sleeping Beauty Transposed PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  29. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    Conditions:   Endocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Neuroendocrine Tumors;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL;   Drug: Pembrolizumab (KEYTRUDA )
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  30. Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy

    Conditions:   Pancreatic Cancer;   Pancreas Cancer;   Ampullary Cancer;   Pancreas Neuroendocrine Tumor;   Pancreatitis;   Distal Extrahepatic Cholangiocarcinoma;   Duodenal Cancer
    Interventions:   Drug: Placebo;   Drug: Pantoprazole
    Sponsor:   Washington University School of Medicine
    Recruiting

  31. A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

    Conditions:   Colorectal Cancer Not MSI-H or MMR-deficient;   GIST;   Oesophageal or Gastric Carcinoma;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Soft-tissue Sarcoma;   Thyroid Cancer;   Gastro-enteropancreatic Neuroendocrine Tumor;   Non-small Cell Lung Cancer;   Solid Tumor, Adult;   Urothelial Carcinoma;   HPV-Related Carcinoma;   Triple Negative Breast Cancer;   Renal Carcinoma;   Mesotheliomas Pleural
    Interventions:   Drug: Phase 1 : Regorafenib;   Drug: Phase 1 : Avelumab;   Drug: Phase 2 : Regorafenib;   Drug: Phase 2 : Avelumab;   Drug: Phase 2: low-dose Regorafenib
    Sponsors:   Institut Bergonié;   Bayer;   Merck KGaA, Darmstadt, Germany
    Recruiting

  32. A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Pralsetinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsor:   Hoffmann-La Roche
    Recruiting

  33. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

  34. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

    Conditions:   Advanced Cancer;   Anal Carcinoma;   Anal Cancer;   Biliary Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Neuroendocrine Tumor;   Carcinoid Tumor;   Endometrial Carcinoma;   Endometrial Cancer;   Cervical Carcinoma;   Cervical Cancer;   Vulvar Carcinoma;   Vulvar Cancer;   Small Cell Lung Carcinoma;   Small Cell Lung Cancer (SCLC);   Mesothelioma;   Thyroid Carcinoma;   Thyroid Cancer;   Salivary Gland Carcinoma;   Salivary Gland Cancer;   Salivary Cancer;   Parotid Gland Cancer;   Advanced Solid Tumors;   Colorectal Carcinoma
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  35. Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

    Conditions:   Carcinoid Syndrome;   Carcinoid;   Carcinoid Tumor;   Carcinoid Tumor of Ileum;   Carcinoid Tumor of Cecum;   Carcinoid Syndrome Diarrhea;   Carcinoid Intestine Tumor;   Carcinoid Tumor of Liver;   Carcinoid Tumor of Pancreas
    Interventions:   Drug: Randomized: 40 mg Paltusotine;   Drug: Randomized: 80 mg Paltusotine
    Sponsor:   Crinetics Pharmaceuticals Inc.
    Recruiting

  36. Study in Patients With Advanced Cancers Associated With Expression of DLL3

    Condition:   Small-cell Lung Cancer
    Interventions:   Drug: HPN328;   Drug: Atezolizumab
    Sponsor:   Harpoon Therapeutics
    Recruiting

  37. A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

    Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

  38. Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

    Condition:   Metastatic Castration-Resistant Prostate Cancer
    Interventions:   Biological: Pembrolizumab 200 mg;   Drug: Olaparib 400 mg;   Drug: Docetaxel 75 mg/m^2;   Drug: Prednisone 5 mg;   Drug: Enzalutamide 160 mg;   Other: Dexamethasone 8 mg;   Drug: Olaparib 300 mg;   Drug: Abiraterone acetate 1000 mg;   Drug: Lenvatinib;   Biological: Pembrolizumab/Vibostolimab coformulation;   Drug: Carboplatin;   Drug: Etoposide;   Biological: Belzutifan 120mg
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  39. Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

    Conditions:   Atypical Teratoid/Rhabdoid Tumor;   Epithelioid Sarcoma;   Kidney Medullary Carcinoma;   Malignant Solid Neoplasm;   Poorly Differentiated Chordoma;   Recurrent Atypical Teratoid/Rhabdoid Tumor;   Recurrent Chordoma;   Recurrent Epithelioid Sarcoma;   Recurrent Kidney Medullary Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Rhabdoid Tumor;   Refractory Atypical Teratoid/Rhabdoid Tumor;   Refractory Chordoma;   Refractory Epithelioid Sarcoma;   Refractory Kidney Medullary Carcinoma;   Refractory Malignant Solid Neoplasm;   Refractory Rhabdoid Tumor;   Rhabdoid Tumor
    Interventions:   Biological: Atezolizumab;   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Other: Fludeoxyglucose F-18;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography;   Biological: Tiragolumab;   Procedure: X-Ray Imaging
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  40. Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study

    Conditions:   Adrenal Gland Pheochromocytoma;   Hematopoietic and Lymphoid System Neoplasm;   Malignant Solid Neoplasm;   Paraganglioma
    Interventions:   Procedure: Computed Tomography;   Drug: Talazoparib;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  41. Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  42. Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

    Condition:   Neurofibromatosis Type 2
    Interventions:   Drug: REC-2282;   Drug: Placebo
    Sponsor:   Recursion Pharmaceuticals Inc.
    Recruiting

  43. BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

    Conditions:   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of the Lung;   Merkel Cell Carcinoma;   Myxoid/Round Cell Liposarcoma
    Intervention:   Biological: CAR-GPC3 T Cells
    Sponsors:   SOTIO, LLC;   SOTIO Biotech
    Recruiting

  44. Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

    Condition:   Merkel Cell Carcinoma
    Interventions:   Drug: KRT-232;   Drug: Avelumab
    Sponsor:   Kartos Therapeutics, Inc.
    Recruiting

  45. Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

    Conditions:   Metastatic Cancer;   Foregut Carcinoid Tumor;   Gastric Adenocarcinoma;   Gallbladder Adenocarcinoma;   Liver Cancer;   GI Cancer;   GI Carcinoma;   Lung Cancer
    Interventions:   Drug: Standard of Care Chemotherapy;   Procedure: Video-Assisted Thoracic Surgery (VATS);   Procedure: Lobectomy;   Radiation: Consolidative Radiation;   Radiation: Ablation Treatment;   Procedure: Resection or Excision;   Procedure: Peritonectomy;   Other: Transarterial Radioembolization
    Sponsor:   University of Chicago
    Not yet recruiting

  46. A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

    Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Choriocarcinoma;   Embryonal Carcinoma;   Immature Teratoma;   Malignant Teratoma;   Mixed Germ Cell Tumor;   Pineal Region Germ Cell Tumor;   Pineal Region Immature Teratoma;   Pineal Region Yolk Sac Tumor;   Suprasellar Germ Cell Tumor
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Mesna;   Biological: Pegfilgrastim;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Procedure: Second-Look Surgery;   Drug: Thiotepa
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting